A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease | Zendy

Laura K. Triantafylidis | Zendy; Chelsea E. Hawley | Zendy; Christopher O Fagbote | Zendy; Jiahua Li | Zendy; Nicole Genovese | Zendy; Julie M. Paik | Zendy

Open Access

A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease

Author(s) -

Laura K. Triantafylidis,

Chelsea E. Hawley,

Christopher O Fagbote,

Jiahua Li,

Nicole Genovese,

Julie M. Paik

Publication year - 2019

Publication title -

journal of pharmacy practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.407

H-Index - 28

eISSN - 1531-1937

pISSN - 0897-1900

DOI - 10.1177/0897190019876499

Subject(s) - medicine , empagliflozin , clinical pharmacy , nephrology , kidney disease , disease , diabetes mellitus , type 2 diabetes , intensive care medicine , family medicine , pharmacy , endocrinology

The American Diabetes Association (ADA) recommends sodium-glucose cotransporter-2 (SGLT2) inhibitors as the second medication to be started, after metformin, for patients with chronic kidney disease (CKD). Sodium-glucose cotransporter-2 inhibitors may cause volume, blood pressure, and electrolyte disturbances; consequently, frequent monitoring and adjustments to other diabetes, blood pressure, and/or diuretic medications may be necessary.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research